One of these OV platforms, Tanapoxvirus (TPV), has been engineered previously to express immuno-modulatory molecules such as mIL-2 and CCL2 [6,7,8] or pathogen-associated molecular patterns (PAMPs) like flagellin C from Salmonella typhimurium (FliC) [9] while deleting viral thymidine kinase (66R) and viral tumor necrosis factor-binding protein (2L) to keep viral replication to tumor cells and potentially increase anti-tumor immune responses. Here, CCL2 is linked to neoplasm.